Fennec Pharmaceuticals Inc SEC Filings

Fennec Pharmaceuticals (FENC) insiders filed a Form 4 reporting multiple open-market sales of common stock across 10/07/2025 to 10/09/2025

Reporting entities tied to Southpoint (Southpoint Capital Advisors LP/LLC, Southpoint GP entities and John S. Clark II) sold a total of 67,114 shares in three tranches at weighted-average prices of approximately $9.5871, $9.4732, and $9.3461. Reported beneficial ownership after each trade was 4,050,314, 4,030,709, and 4,010,100 shares respectively. The filing explains that the shares are held directly by Southpoint Master Fund, LP and that the reporting persons disclaim beneficial ownership except for pecuniary interest.

Insider exercised options to buy 4,609 common shares at $2.45, increasing direct beneficial ownership to 87,110 shares. The transaction was executed on 10/08/2025 via exercise of stock options that carry a $2.45 strike and expire on 07/05/2026. After the exercise the reporting person holds 4,609 underlying options shown as exercised and 1,634,184 remaining outstanding options in the same class per the filing table. The form is a Section 16 filing by a director, showing a routine option exercise rather than a market sale or open-market purchase.

Insider sale by director: A director, Rosty Raykov, reported the sale of 10,000 common shares of FENNEC PHARMACEUTICALS INC. (FENC) on 10/06/2025 at a price of $9.78 per share. The filing states the shares were sold under a 10b5-1 plan dated 08/23/2024, indicating the transactions were pre-planned. After the sale, the reporting person beneficially owns 82,501 shares, held directly. The form is a standard Section 16 disclosure by a company director and does not include other derivative transactions.

Fennec Pharmaceuticals, Inc. (FENC) reported a proposed insider sale under Rule 144: 10,000 common shares planned for 10/06/2025 through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $97,868. The issuer shows 27,831,698 shares outstanding, so the proposed sale equals approximately 0.036 of outstanding shares.

The filer acquired the 10,000 shares as restricted stock in three tranches on 05/16/2025 (5,485 shares), 05/31/2025 (2,085), and 09/30/2025 (2,430), all issued by the company. The notice also discloses two prior sales by the same person in the past three months: 10,000 shares sold on 09/04/2025 for $89,220 and 10,000 shares sold on 08/05/2025 for $80,933. The filer attests not to possess undisclosed material adverse information.

Rosty Raykov, a director of Fennec Pharmaceuticals Inc. (FENC), reported a non‑derivative acquisition of 5,208 common shares on 09/30/2025 at a reported price of $0. The filing states these shares were released from restrictions tied to awards granted on 03/31/2023 and 05/16/2024. After the release, Mr. Raykov beneficially owns 92,501 shares of common stock. The Form 4 was filed by one reporting person and lists Mr. Raykov’s relationship to the issuer as a director. The transaction appears to be the routine vesting or release of previously awarded restricted stock rather than an open‑market purchase or sale.

Robert Andrade, Chief Financial Officer of Fennec Pharmaceuticals (FENC), reported the release of 2,430 common shares from restrictions on 09/30/2025 at a reported price of $0, reflecting shares awarded previously on 03/31/2023 and 05/16/2024. After this transaction Andrade beneficially owns 170,674 common shares. The Form 4 was signed on 10/01/2025. The filing shows a routine internal release of restricted awards rather than an open-market purchase or sale and documents current insider ownership levels for compliance with Section 16 reporting.

Rosty Raykov, a director of Fennec Pharmaceuticals Inc. (FENC), exercised stock options on 09/05/2025. He exercised 36,207 options with a $2.45 strike, resulting in 36,207 common shares acquired and increasing his total beneficial ownership to 87,293 shares. The options exercised had an exercise price of $2.45 and an expiration date of July 5, 2026; the filing lists a date exercisable of July 5, 2016. The Form 4 was signed on 09/08/2025 and reports the transaction as a direct ownership change by one reporting person.

Fennec Pharmaceuticals (FENC) Form 144 reports a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney on 09/04/2025 with an aggregate market value of $89,220.00. The filing lists total outstanding shares of 27,831,698, showing the proposed block is a small fraction of the float.

The shares to be sold were acquired as restricted stock from the issuer: 7,570 shares on 05/16/2025 and 2,430 shares on 08/31/2025, totaling 10,000. The filer also disclosed three prior sales in the past three months of 10,000 shares each on 06/05/2025, 07/03/2025, and 08/05/2025 with gross proceeds of $77,781, $86,102, and $80,933 respectively.

Rosty Raykov, a director of Fennec Pharmaceuticals Inc. (FENC), reported a sale of 10,000 common shares on 09/04/2025 at a reported price of $8.92 per share. The Form 4 indicates the sale was made pursuant to a 10b5-1 plan dated August 23, 2024. Following the reported transaction, Mr. Raykov beneficially owns 51,086 shares, held directly. The filing is a routine insider reporting disclosure of this transaction.